Please use this identifier to cite or link to this item: http://ahro.austin.org.au/austinjspui/handle/1/11406
Title: A multicentre, randomized, double-blinded, placebo-controlled Phase III study to investigate EXtending the time for Thrombolysis in Emergency Neurological Deficits (EXTEND).
Authors: Ma, Henry K;Parsons, Mark W;Christensen, Soren;Campbell, Bruce C V;Churilov, Leonid;Connelly, Alan;Yan, Bernard;Bladin, Christopher;Phan, Than;Barber, P Alan;Read, Stephen;Hankey, Graeme J;Markus, Romesh;Wijeratne, Tissa;Grimley, R;Mahant, N;Kleinig, Tim;Sturm, John;Lee, A;Blacker, D;Gerraty, Richard;Krause, M;Desmond, Patricia M;McBride, S J;Carey, Leeanne M;Howells, David William;Hsu, C Y;Davis, Stephen M;Donnan, Geoffrey A
Institutional Author: EXTEND investigators
Affiliation: National Stroke Research Institute, Florey Neuroscience Institutes, Austin Health, University of Melbourne, Heidelberg Heights, Victoria, Australia.
Issue Date: 1-Jan-2012
Citation: International Journal of Stroke : Official Journal of the International Stroke Society; 7(1): 74-80
Abstract: Thrombolytic therapy with tissue plasminogen activator is effective for acute ischaemic stroke within 4·5 h of onset. Patients who wake up with stroke are generally ineligible for stroke thrombolysis. We hypothesized that ischaemic stroke patients with significant penumbral mismatch on either magnetic resonance imaging or computer tomography at three- (or 4·5 depending on local guidelines) to nine-hours from stroke onset, or patients with wake-up stroke within nine-hours from midpoint of sleep duration, would have improved clinical outcomes when given tissue plasminogen activator compared to placebo.EXtending the time for Thrombolysis in Emergency Neurological Deficits is an investigator-driven, Phase III, randomized, multicentre, double-blind, placebo-controlled study. Ischaemic stroke patients presenting after the three- or 4·5-h treatment window for tissue plasminogen activator and within nine-hours of stroke onset or with wake-up stroke within nine-hours from the midpoint of sleep duration, who fulfil clinical (National Institutes of Health Stroke Score ≥4-26 and prestroke modified Rankin Scale <2) will undergo magnetic resonance imaging or computer tomography. Patients who also meet imaging criteria (infarct core volume <70 ml, perfusion lesion : infarct core mismatch ratio >1·2, and absolute mismatch >10 ml) will be randomized to either tissue plasminogen activator or placebo.The primary outcome measure will be modified Rankin Scale 0-1 at day 90. Clinical secondary outcomes include categorical shift in modified Rankin Scale at 90 days, reduction in the National Institutes of Health Stroke Score by 8 or more points or reaching 0-1 at day 90, recurrent stroke, or death. Imaging secondary outcomes will include symptomatic intracranial haemorrhage, reperfusion and or recanalization at 24 h and infarct growth at day 90.
Internal ID Number: 22188854
URI: http://ahro.austin.org.au/austinjspui/handle/1/11406
DOI: 10.1111/j.1747-4949.2011.00730.x
URL: http://www.ncbi.nlm.nih.gov/pubmed/22188854
Type: Journal Article
Subjects: Double-Blind Method
Female
Fibrinolytic Agents.administration & dosage
Humans
Magnetic Resonance Imaging
Male
Middle Aged
Research Design
Stroke.drug therapy.pathology
Thrombolytic Therapy.methods
Time Factors
Tissue Plasminogen Activator.administration & dosage
Tomography, X-Ray Computed
Appears in Collections:Journal articles

Files in This Item:
There are no files associated with this item.


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.